MEDP is trading 4.3% down at $522.99 after Jefferies downgraded the stock from Buy to Hold, citing valuation concerns and potential downside risk.

  • Jefferies established a price target of $515.00, noting a disconnect between the current share price and achievable fundamentals.
  • Analysts highlighted stretched multiples and a depleted reservoir of potential bookings as key factors prompting investors to reassess the stock.